How to Source Lorlatinib for Pharmaceutical Formulation

Lorlatinib (Tablets, 25 mg, 50 mg,100 mg) is classified under Oncology Cancer Care. It is therapeutically aligned with reference brands such as Lorbrena (USA). This guide highlights key sourcing factors buyers should consider when procuring high-quality Lorlatinib for formulation, R&D, or bulk manufacturing.

Product Overview: Lorlatinib, marketed under the brand names Lorbrena in the USA, Canada, and Japan, and Lorviqua in t...

1. Regulatory Compliance & Documentation

Ensure suppliers provide:

• ✔ Valid DMF (Drug Master File)
• ✔ COA (Certificate of Analysis) for each batch
• ✔ GMP, ISO, or ICH Q7 compliance certificates

2. Purity, Grade & Specification Matching

Lorlatinib must meet exact grade and purity for your dosage form:

• ✔ USP / EP / JP grade verification
• ✔ Particle size distribution check
• ✔ Residual solvent and heavy metal limits

3. Supplier Reliability & Audit History

• ✔ Positive past audit reports
• ✔ Pharma client references
• ✔ Years of proven API manufacturing experience

4. Commercial Terms: Pricing, MOQ & Flexibility

• ✔ Transparent pricing
• ✔ Pilot batch MOQ flexibility
• ✔ Volume-based discounts

5. Lead Time, Inventory & Logistics

Typical lead time for Lorlatinib is 4–6 weeks.

• ✔ Emergency dispatch options
• ✔ Regional warehousing
• ✔ Special storage if needed

6. Formulation Support

• ✔ Technical datasheets
• ✔ Sample availability
• ✔ Stability study support

Conclusion

Sourcing Lorlatinib is more than procurement—it’s a strategic partnership. With its tablets form and 25 mg, 50 mg,100 mg specification, choosing a compliant supplier ensures consistent quality and regulatory approval. Prioritize documentation, verify compatibility, and build relationships with transparent, reliable suppliers to secure long-term success.

Frequently Asked Questions For Sourcing of Lorlatinib